Keyphrases
Heart Failure
70%
Patients with Heart Failure
26%
Acute Decompensated Heart Failure
25%
Left Ventricular Assist Device
25%
Heart Failure Patients
24%
Heart Transplantation
24%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
20%
Heart Failure with Preserved Ejection Fraction (HFpEF)
18%
Heart Transplant Recipients
18%
Confidence Interval
14%
Continuous-flow Left Ventricular Assist Device (CF-LVAD)
12%
Empagliflozin
12%
Left Ventricular Ejection Fraction
12%
Pulmonary Capillary Wedge Pressure
12%
Chronic Heart Failure
11%
Solid Organ Transplant Recipients
11%
Everolimus
10%
Reduced Ejection Fraction
10%
During Exercise
10%
Systolic Heart Failure
9%
Left Ventricular Assist Device Implantation
9%
Acute Heart Failure
9%
Hazard Ratio
9%
All-cause Mortality
9%
Invasive Hemodynamics
9%
Quality of Life
9%
Clinical Consensus Statement
9%
European Society of Cardiology
8%
Myocardial Infarction
8%
Atrial Fibrillation
8%
Preserved Ejection Fraction
8%
Calcineurin Inhibitors
8%
Hospitalization
8%
Heart Failure Clinic
8%
Randomized Clinical Trial
8%
Placebo
7%
Mechanical Circulatory Support
7%
National Cohort Study
7%
Beta-blockers
7%
Implantable Defibrillator
7%
Transplantation
7%
Patients with Chronic Heart Failure
6%
Comorbidity
6%
Type 2 Diabetic Patients
6%
AIMS™
6%
Congestive Heart Failure
6%
Randomized Controlled Trial
6%
Heart Transplant
6%
Peripartum Cardiomyopathy
6%
Solid Organ Transplantation
6%
Medicine and Dentistry
Heart Failure
100%
Left Ventricular Assist Device
42%
Hemodynamic
30%
Heart Transplantation
26%
Ejection Fraction
23%
Heart Graft
20%
Congestive Heart Failure
20%
Transplantation
16%
Cardiovascular System
15%
Assisted Circulation
12%
Empagliflozin
11%
Systolic Heart Failure
11%
Heart Left Ventricle Ejection Fraction
11%
Amino Terminal Sequence
11%
Brain Natriuretic Peptide
11%
Quality of Life
10%
Placebo
10%
Outpatient
9%
Calcineurin Inhibitor
9%
Pulmonary Artery Occlusion Pressure
9%
Cardiology
9%
Exercise
9%
Everolimus
8%
Acute Decompensated Heart Failure
8%
Atrial Fibrillation
8%
Adverse Event
8%
Randomized Clinical Trial
8%
Prevalence
8%
Implantable Automatic Defibrillator
7%
Biological Marker
7%
Heart Failure with Preserved Ejection Fraction
7%
Oxygen Consumption
7%
Hazard Ratio
6%
Combination Therapy
6%
Cardiac Allograft Vasculopathy
6%
Peripartum Cardiomyopathy
6%
Transthyretin
6%
Randomized Controlled Trial
6%
Diagnosis
6%
Glomerular Filtration Rate
5%
Heart Failure with Reduced Ejection Fraction
5%
Infection
5%
Cardiac Catheterization
5%
New York Heart Association Class
5%
Systematic Review
5%
Heart Left Atrium Pressure
5%
Immunosuppressive Treatment
5%
Apoplexy
5%
Heart Function
5%